Its therapeutic approach is designed to take advantage of a cancer cells innate metabolic weaknesses to cause cancer cell death. The stock price of TYME Technologies Inc (NASDAQ: TYME) surged by over 40 pre-market today. Will TYME be a Portfolio Killer in July Zacks Investment Research is releasing its prediction for TYME based on the 1-3 month trading. Learn More on Tyme Technologiess short interest ratio. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. TYME shares currently have a short interest ratio of 1.0. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SM-88 is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. It is focused on developing its novel compound, SM-88 and its preclinical pipeline of novel CMBT programs. The Company is developing cancer metabolism-based therapies (CMBTs ) that are effective across a broad range of solid tumors and hematologic cancers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |